Shire to take on hemophilia marketing with long-sought Baxalta buy

Baxalta ($BXLT) and its portfolio of hemophilia meds are finally destined to join the fold at Shire ($SHPG). Monday, the two companies announced a $32 billion tie-up after a months-long pursuit by the Dublin drugmaker. More from FiercePharma

Read more on